Research has found that KRAS mutations are present in 30 percent of non-small cell lung cancers (NSLC) and in 40 to 50 percent of colorectal cancers. This mutation prevalence has been linked to poor survival rates and chemotherapy resistance within the impacted oncology cohorts. In an attempt to remedy this known issue, researchers at University of California, San Diego screened KRAS mutant cells for synthetic lethal interactions (https://www.genomeweb.com/cancer/kras-driven-tumor-growth-inhibited-microrna). Results concluded that the miR-1298 gene when inhibited is lethal to the growth of KRAS-mutated cells, both in vitro and in vivo through a combination of microarray analyses.
At BIOIVT, we understand the importance of mutation analysis in cancer research.Developing therapies that are targeted to specific genetic biomarkers reduces the toxicological imprint on the target population and increases the survival rate. In an effort to support current research efforts, our scientists routinely perform DNA and RNA isolation from both FFPE and Fresh Frozen tissues, as well as biofluids. Additionally, we utilize PCR, FISH, and IHC for the determining the presence and/or location of particular mutations and proteins within tissue specimens. Standard mutation analysis is available for lung, skin, and colon cancers, with custom mutation screens available upon request.
For more information on how we can help you with your tissue and /or mutation analysis needs, please feel free to contact us.